Description of the GiACTA trial (Stone et al, N. Engl. J. Med. 2017), a Phase III clinical trial of tocilizumab (Actemra) for the treatment of giant cell arteritis (GCA).

Description of the GiACTA trial (Stone et al, N. Engl. J. Med. 2017), a Phase III clinical trial of tocilizumab (Actemra) for the treatment of giant cell arteritis (GCA).
Today is the 4th anniversary of my diagnosis. It looks like my vasculitis is not going anywhere, but neither am I.
Announcing the 19th International Vasculitis and ANCA Workshop April 7-10 2019, Philadelphia, PA USA.
Description of the MIRRA trial (Wechsler et al, N. Engl. J. Med. 2017), a Phase III clinical trial of mepolizumab (Nucala) for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA/Churg-Strauss Syndrome).
How do the IL-5 inhibitors Cinqair (reslizumab), Fasenra (benralizumab), and Nucala (mepolizumab) work? How do they control eosinophils?
Treatment ups and downs for my EGPA/Churg-Strauss vasculitis from Oct 2014 through Apr 2018 detailing prednisone tapers, treatment modifications, and flares.
GSK educational video on living with #raredisease EGPA.
Getting a diagnosis is just the first step. Here's the story of my diagnosis with EGPA/Churg-Strauss vasculitis.
Patient webinar about diagnosis with EGPA/Churg-Strauss vasculitis, treatment, tracking symptoms, working with doctors, and strategies for managing vasculitis.